Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
Genetic Testing Firms Stocks$317.47
-1.07%4:00PM 03/08/2021
The list of companies include MYGN-Myriad Genetics, Inc., NVTA-Invitae Corp, NTRA-Natera Inc, DGX-Quest Diagnostics, Inc., LH-Laboratory Corp. Of America Holdings, CODX-Co-Diagnostics Inc, OCX-OncoCyte Corp, CGIX-Cancer Genetics Inc., NEOG-Neogen Corp., PRPO-Precipio Inc, FLGT-Fulgent Genetics Inc, VCYT-Veracyte Inc
Latest intraday update before market close @ 20:44:58 PM 03/08/2021
Summary :
Average return is down -0.9%
Median return is down -0.3%
6 out of 13 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information


  • Genetic Testing Firms stocks down 1.1% on average while median return down 0.6% in a day
  • Genetic Testing Firms stocks down 14.0% on average while median return down 15.3% in a week
  • Genetic Testing Firms stocks down 13.0% on average while median return down 19.8% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

1 Day Return
1 Week Return
1 Month Return
PE Ratio
PE Growth Ratio
Price to Book (mrq)
Price to Sales (ttm)
Earning Growth
Short %
Held By Institutions %
Price Pattern
Days Since Channel Change
Channel Slope (daily rate %)
Half Channel Bandwidth
Distance to Channel MidPoint %

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $CGIX 28.4%, $LH 7.5%
  • 1M losers are : Losers for past month are $FLGT -20.8%, $OCX -30.5%, $NVTA -30.8%, $PRPO -31.3%, $VCYT -42.9%
  • 1W winners are : Winners for past week are $DGX 3.9%
  • 1W losers are : Losers for past week are $PRPO -17.0%, $NVTA -20.5%, $NTRA -24.4%, $OCX -24.4%, $VCYT -29.3%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 20.9%, for the past 3 months is 19.4%

In the past month for a 5 days rolling window, the highest corrrelation is 40.2%, the lowest correlation is -3.1%, the latest correlation is 28.9%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 74.2% between CODX and PRPO

The lowest correlation is -37.3% between CODX and DGX

Stock news

    Why Fulgent Genetics Stock Temporarily Soared 31% Today

    The genetic testing company reported revenue of $295 million with adjusted earnings of $167.5 million, or $6.20 per share. Fulgent also provided 2021 guidance that projects 90% revenue growth this year. Most of Fulgent's tremendous revenue increase came from its COVID-19 testing business.

    Myriad Genetics (MYGN) Collaborates to Advance Oncology Care

    Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

    Does Invitae Have a Path to Profitability?

    Invitae (NYSE: NVTA) is growing revenue quickly thanks to its acquisition of ArcherDx, which offers tests to determine the best drugs to treat tumors. In this video from Motley Fool Live, recorded on Feb. 22, contributors Brian Orelli and Keith Speights discuss how Invitae's top-line growth should eventually benefit the company's bottom line.

    Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference

    TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, Marc...

    COVID Tester Fulgent Higher on Earnings Beat and Guidance

    Fulgent Genetics, a provider of COVID-19 testing services, beat Wall Street's fourth-quarter-earnings expectations.

    How Fulgent Genetics Wowed With Its Q4 Results

    The genetic-testing company provided its fourth-quarter update after the market close on Thursday. In the prior-year period, Fulgent posted a GAAP net loss of $296 million, or $0.01 per share. COVID-19 is pretty much all you need to know about Fulgent's stellar fourth-quarter results.

    Fulgent Genetics, Inc. Common Stock (FLGT) Q4 2020 Earnings Call Transcript

    FLGT earnings call for the period ending December 31, 2020.

    These 2 Stocks Are Soaring Despite Another Market Plunge

    Declines for the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) were substantial, but the indexes finished well above their worst levels. Fulgent Genetics (NASDAQ: FLGT) and T2 Biosystems (NASDAQ: TTOO) both moved sharply higher after reporting solid earnings results. Fulgent Genetics fell 8% in the regular session, but its stock had jumped 33% as of 5 p.m. EST in after-hours trading.

    Recap: Fulgent Genetics Q4 Earnings

    Shares of Fulgent Genetics (NASDAQ:FLGT) moved higher by 24.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05. Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000. Guidance Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est. Details Of The Call Date: Mar 04, 2021 Time: 04:30 PM View more ea...